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The discovery of polymyxins, highly basic lipodecapeptides, was published
independently by three laboratories in 1947. Their clinical use, however, was abandoned
in the sixties because of nephrotoxicity and because better-tolerated drugs belonging
to other antibiotic classes were discovered. Now polymyxins have resurged as the last-
resort drugs against extremely multi-resistant strains, even though their nephrotoxicity
forces clinicians to administer them at doses that are lower than those required for
optimal efficacy. As their therapeutic windows are very narrow, the use of polymyxins
has received lots of justified criticism. To address this criticism, consensus guidelines for
the optimal use of polymyxins have just been published. Quite obviously, too, improved
polymyxins with increased efficacy and lowered nephrotoxicity would be more than
welcome. Over the last few years, more than USD 40 million of public money has
been used in programs that aim at the design of novel polymyxin derivatives. This
perspective article points out that polymyxins do have potential for further development
and that the novel derivatives already now at hand might offer major advantages over
the old polymyxins.
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INTRODUCTION: THE OLD POLYMYXINS
In 2010, the World Health Organization (WHO) stated that antibiotic resistance is one of the three
greatest threats to human health. Many strains of Gram-negative bacteria have now developed
resistance to practically all currently used antibacterial agents, including carbapenems. These
strains are spreading globally and this narrows down the therapeutic options (Theuretzbacher,
2017; Wright et al., 2017; Bonomo et al., 2018; Tumbrarello et al., 2018; Cox et al., 2019;
Koulenti et al., 2019). At the same time the few agents that remain potentially usable do have
their defects, too. Low serum and urine levels shadow the use tigecycline (Tumbrarello et al.,
2018). Ceftazidime–avibactam (CZA), imipenem–cilastatin–relebactam (I–R), and meropenem–
vaborbactam (MVB) are not effective against strains that produce carbapenemases belonging to
the metallo-beta-lactamase group, i.e., to Class B beta-lactamases (Wright et al., 2017; Tumbrarello
et al., 2018; Koulenti et al., 2019). Furthermore, Class A carbapenemase-producing KPC strains
that are mutationally resistant to CZA are emerging, and resistance is observed following relatively
short courses of therapy (Shields et al., 2017; Wright et al., 2017; Tumbrarello et al., 2018). CZA
is the eldest of the novel beta-lactam/beta-lactamase inhibitor combinations, and the question
arises, whether a similar resistance development will be seen with the newer beta-lactam–
beta-lactamase inhibitor combinations such as I–R, MVB, and the related derivatives (Wright
et al., 2017). The neoaminoglycoside plazomicin entered the clinics in 2018 but it is not active
against strains in which the target is altered due to 16S rRNA methylation (Wright et al., 2017;
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Theuretzbacher and Paul, 2018; Koulenti et al., 2019). Future does
not look bright, as today only a few novel antibiotics against
the extremely drug-resistant Gram-negative bacteria are under
development (WHO, 2019).
Polymyxins are cyclic lipodecapeptide antibiotics (Figure 1
and Table 1). Out of this group, polymyxin B (PMB) and colistin
(administered as an antibacterially inactive prodrug colistin
methanesulfonate, also known as colistimethate, CMS) are in
current clinical use. They are highly basic due to their five
free amino groups and quite effective against Gram-negative
bacteria, such as the majority of Enterobacteriaceae, as well
as Acinetobacter baumannii and Pseudomonas aeruginosa.
Polymyxins act specifically on Gram-negative bacteria and are
rapidly bactericidal, while Gram-positive bacteria, eukaryotic
microbes, and mammalian cells are typically unaffected
(HsuChen and Feingold, 1973). The antibacterial potencies
of PMB and colistin are identical (Gales et al., 2011; Sader
et al., 2015). Polymyxins first interact with the anionic
lipopolysaccharide (LPS) molecules, exclusively present in
Gram-negative bacteria and located in the outer leaflet of their
outer membrane (OM), as reviewed by Vaara (1992). The lipid
A part of LPS carries anionic phosphate and pyrophosphate
groups, and the cationic polymyxins bind into these groups
(Vaara, 1992). This interaction results in the release of LPS and
the disorganization, restructuring, and generation of cracks in
the OM, leading to loss of function as a permeability barrier.
In electron micrographs, polymyxins cause blebbing of the OM
vesicles outside the cell as well as typical “fingerlike projections”
in the OM (Vaara, 1992). Furthermore, polymyxins cause leakage
of the periplasmic contents, such as beta-lactamases, and make
the OM permeable the many noxious agents such as antibiotics
and lysozyme (Vaara, 1981, 1992). The final and lethal action of
polymyxins is the damage to the cytoplasmic membrane. They
cause leakage of cytoplasmic contents such as ATP (Murray
et al., 2016). Additional possible mechanisms include inhibition
of NADH-quinone oxidoreductase activity (Deris et al., 2014) as
well as production of hydroxyl radicals (Sampson et al., 2012)
and reactive oxygen species (Imlay, 2013).
The clinical use of polymyxins was abandoned in the
sixties because of nephrotoxicity and because better-tolerated
drugs belonging to other antibiotic classes were discovered.
Now, however, polymyxins have resurged as the last-resort
drugs against extremely multi-resistant strains, even though
their nephrotoxicity forces clinicians to administer them at
doses that are lower than those required for optimal efficacy.
The currently used polymyxins are drugs with very narrow
therapeutic windows (Nation et al., 2019). Very recently,
consensus guidelines for the optimal use of the polymyxins
have been published (Tsuji et al., 2019). Recommendations
were given on many important issues such as the dosing
of polymyxins. In the therapy of invasive infections, PMB
appears to be less nephrotoxic than CMS and hence preferred
(Nation et al., 2019; Tsuji et al., 2019). Furthermore, PMB
seems to have superior pharmacokinetic characteristics for
infections in which it is important to achieve the desired
concentration in plasma rapidly and reliably and to maintain
it as well (Tsuji et al., 2019). In the therapy of lower
urinary tract infections (i.e., bladder infections, cystitis), the
bacteriologically inactive prodrug CMS is preferred, because
it is effectively excreted into the bladder and subsequently
hydrolyzed there to the bacteriologically active form, i.e., colistin
(Tsuji et al., 2019). However, its pharmacokinetics, including
the hydrolysis to active drug, shows substantial interpatient
variability and this makes the choice of the proper dose difficult
(Tsuji et al., 2019).
Polymyxin B and colistin are effectively bound to the
brush-border membrane (BBM) of the proximal tubular kidney
cells and taken up (reabsorbed) by these cells (Moestrup
et al., 1995). At the molecular level, the binding and uptake
takes place via the megalin-mediated endocytosis (Moestrup
et al., 1995; Suzuki et al., 2013; Abdelraouf et al., 2014) but
very recent studies indicate that human peptide transporter 2
(PEPT2) and carnitine/organic cation transporter 2 (OCTN2)
are involved as well (Lu et al., 2016; Visentin et al., 2017). Once
taken up by the cells, polymyxins inhibit the mitochondrial
electron transport, i.e., respiration (as reviewed by Gai et al.,
2019), cause increased superoxide production (Nation et al.,
2019), and activate caspases that lead to cellular apoptosis
(Visentin et al., 2017). Polymyxins also upregulate the cholesterol
biosynthesis in the kidney cells (Weber et al., 2018). Whether
this is an attempt to protect cells remains to be elucidated.
Regarding protection, there have been many attempts to reduce
the nephrotoxicity of polymyxins by adding simultaneously
antioxidants (Gai et al., 2019; Nation et al., 2019). According
to the consensus paper, the current data are insufficient
to recommend routine administration of ascorbic acid or
any other antioxidant for the prevention of nephrotoxicity
(Tsuji et al., 2019).
IMPROVED POLYMYXINS
Even though the value of the polymyxins now used in the
clinics is acknowledged, novel derivatives that are more effective
and less toxic would be more than welcome. It should be
noted that most of the antibiotics of the “golden age of
antibiotic discovery” have now been replaced by their improved
versions. That has happened to the archetypical beta-lactam
antibiotic penicillin G; the first cephalosporin, cephalothin;
the first tetracycline, chlortetracycline; the first aminoglycoside
antibiotic streptomycin; and the first macrolide antibiotic
erythromycin. The first clinically used antibacterial quinolone,
nalidixic acid, was followed by a wide variety of better quinolones
and fluoroquinolones. However, some of the antibiotic classes
discovered decades ago have not yet been developed any further
but are still in current use. These ancient “dinosaurs” of the
antibiotic world include polymyxins.
One case has perhaps shadowed the development of improved
polymyxins. The development of Cubist’s CB-182 804 (Table 1)
was discontinued in 2010 after the Clinical Phase 1, apparently
because of toxicity issues. It differed from PMB only by
carrying a different fatty acyl group linked to the peptide part.
Later on, Pfizer published their discovery that replacement
of diaminobutyric acid (Dab) at the position R3 in the
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FIGURE 1 | The structure of polymyxin B1. The fatty acyl tail is highlighted with yellow, the linear “panhandle” part (i.e., the residues R1–R3) with pink, and the cyclic
heptapeptide part (i.e., residues R4–R10) with blue.
TABLE 1 | The structures of polymyxin B, colistin, and the novel polymyxin derivatives that display improved efficacy in animal infection models (compounds 4–10)a,b.
Compound R (FA) R1 R2 R3 R4 R5 R6 R7 R8 R9 R10
1 Polymyxin B (PMB) Methyloctanoyl/methylheptanoyl -Dab+ -Thr -Dab+ -cy[Dab -Dab+ -DPhe -Leu -Dab+ -Dab+ -Thr]
2 Colistin (polymyxin E) Methyloctanoyl/methylheptanoyl -Dab+ -Thr -Dab+ -cy[Dab -Dab+ -DLeu -Leu -Dab+ -Dab+ -Thr]
3 CB-182,804 2-chloro-phenylamino-carbonyl -Dab+ -Thr -Dab+ -cy[Dab -Dab+ -DPhe -Leu -Dab+ -Dab+ -Thr]
4 FADDI-002 Octanoyl -Dab+ -Thr -Dab+ -cy[Dab -Dab+ -DPhe -Ada -Dab+ -Dab+ -Thr]
5 FADDI-287 Octanoyl -Dab+ -Thr -Dap+ -cy[Dab -Dab+ -DLeu -Abu -Dab+ -Dab+ -Thr]
6 CA824 (S)-1-(2-methylpropyl)-piperazine-2-carbonyl+ – -Thr -Dab+ -cy[Dab -Dab+ -DPhe -Leu -Dab+ -Dab+ -Thr]
7 SPR206 (3S)-4-amino-3-(3-chlorophenyl)butanoyl – -Thr -Dab+ -cy[Dab -Dab+ -DPhe -Leu -Dab+ -Dab+ -Thr]
8 MicuRx-12 3-(2,2-dimethyl-butanoyloxy)-propanoyl (ester bond) -Dab+ -Thr -Dab+ -cy[Dab -Dab+ -DPhe -Leu -Dab+ -Dab+ -Thr]
9 NAB739 Octanoyl – -Thr -DSer -cy[Dab -Dab+ -DPhe -Leu -Dab+ -Dab+ -Thr]
10 NAB815 Octanoyl -Dab+ -Thr -DThr -cy[Dab -Dab+ -DPhe -Leu -Abu -Dab+ -Thr]
11 SPR741 (NAB741) Acetyl – -Thr -DSer -cy[Dab -Dab+ -DPhe -Leu -Dab+ -Dab+ -Thr]
The structure of one discontinued derivative (compound 3) as well as that of the potentiator compound SPR741 (NAB741) are also shown. aAmino acyl residues
that differ from those in polymyxin B are boxed. bAbu, aminobutyryl; Ada, aminodecanoyl; Dap, diaminopropionyl; cy, cyclic portion indicated with brackets; Dab,
diaminobutyryl; FA, fatty acyl.
polymyxin peptide with diaminopropionic acid (Dap) (Table 1)
reduced the cytotoxicity to kidney cell cultures and rat kidneys
(Magee et al., 2013). However, this difference did not translate to
dogs (Magee et al., 2013), and Pfizer dropped the program. Astra-
Zeneca has also discontinued their polymyxin program (chemical
structures not revealed).
On the other hand, there are others who do believe that
polymyxins have potential for further development and recently
many attempts have been made to design more effective and
better tolerated derivatives. This work has been portrayed in
extensive reviews (Vaara, 2013, 2018; Brown and Dawson, 2017;
Rabanal and Cajal, 2017; Gallardo-Godoy et al., 2019).
Northern Antibiotics (NAB) made the strategic decision
to develop less nephrotoxic derivatives that carry three
positive charges only, in contrast to five in the old
polymyxins. They showed that binding of PMB to kidney
BBM (see above) does correlate with the number of
positive charges in the molecule (Vaara et al., 2008;
Shapiro, 2013). NAB739 and NAB815 (Table 1) are less
nephrotoxic than PMB in cynomolgus monkeys (Vaara, 2018).
Furthermore and quite importantly, both compounds are
thus far the only polymyxins effectively excreted into urine
(Vaara, 2018).
FADDI-02, FADDI-287, CA824, MicuRx-12, and SPR206
[formerly CA1206] (for the structures of these compounds, see
Table 1) are superior to the old polymyxins in the rodent lung
infection model with A. baumannii and/or P. aeruginosa (Velkov
et al., 2014; Boakes et al., 2015; Gordeev et al., 2016; Brown and
Dawson, 2017; Grosser et al., 2018b). In Escherichia coli systemic
infection in mice, MicuRx-12 is slightly more effective than PMB
(Gordeev et al., 2016). In mouse urinary tract E. coli infection,
SPR206 displays activity similar or slightly superior compared to
PMB (Grosser et al., 2018a) while the effective dose of NAB739
and NAB815 is only one-tenth of that of PMB (Vaara et al., 2018).
SPR206 (now in Clinical Phase 1) has an altered fatty acyl tail
and a shortened linear part and appears to be less nephrotoxic
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than PMB in cynomolgus monkeys (Lister et al., 2018). Regarding
several other derivatives, more results in non-human primates
are awaited as the lowered nephrotoxicity has thus far been
demonstrated only in rodents for the FADDI compounds (Sabet
et al., 2016) which have altered amino acyl groups in the cyclic
and linear parts, and for MicuRx-12 (Gordeev et al., 2016) in
which the fatty acyl tail is linked to the cyclic part via an ester
bond. In plasma, this ester bond enables the decomposition
of the compound to a tail-less and apparently less toxic
metabolite. Whether therapeutically effective amounts of the
intact compound reach the infection focus before decomposition
in indications such as complicated urinary tract infection (cUTI)
remains to be evaluated. The ester bond compound MRX-8 is
now reported to be in investigational new drug (IND)-enabling
studies (Gordeev, 2018).
The U.S. National Institute of Allergy and Infectious
Diseases (NIAID) has since 2012 funded the Monash University
(Melbourne, Australia) by more than USD 25 million in
programs that aim at the discovery of new polymyxins and
the re-development of the old ones. This funding continues.
The group of Prof. Roger Nation and Prof. Jian Li at the
Monash University is today the world leader in polymyxin
studies. In addition, NIAID has supported the preclinical studies
on SPR206 by USD 6.3 million. Furthermore, the transatlantic
funding instrument CARB-X that aims at accelerating global
antibacterial innovation has recently granted MicuRx USD
5.2 million to be used in further development of their
polymyxin derivatives.
Other examples attesting the hopes put on polymyxins
include SPR741 (formerly NAB741; Vaara, 2019; Table 1)
which passed successfully Clinical Phase 1 in late 2017. In
contrast to other derivatives under development, SPR741 lacks
the direct antibacterial activity, i.e., it is not bactericidal.
However, it does sensitize the targets to more than 10
different partner antibiotics, normally active against Gram-
positive bacteria only. Furthermore, it is synergistic with
several beta-lactam antibiotics that are effective against Gram
negatives, too. It is an excellent model for polymyxins
that damage the outermost cell surface barrier, the OM
and permeabilize it to other antibiotics. In 2017, CARB-
X granted Spero Therapeutics USD 5.4 million for further
studies on SPR741.
As a great number of research groups are currently
developing novel polymyxin derivatives, one crucial practical
aspect is worth noticing. The in vitro susceptibility studies
in which novel polymyxin derivatives under development are
compared to the old polymyxins and to each other are
more demanding than many other susceptibility studies. The
activity of polymyxins varies greatly depending on the test
conditions used, including the choice of the growth medium.
Furthermore, polymyxins are in a very significant degree
adsorbed to (i.e., inactivated by) polystyrene microwell plates
and other laboratory plastics in a time-dependent fashion
(Karvanen et al., 2017; Poirel et al., 2017; Gallardo-Godoy
et al., 2019). To enable proper comparison of the results, all
research laboratories that develop novel polymyxins should
use the CLSI/EUCAST standard that is currently used in the
clinical laboratories in the determination of susceptibility to
the old polymyxins. Accordingly, in the broth microdilution
(BMD) method, cation-adjusted Mueller–Hinton broth (CA-
MHB) should be used. To minimize the effect of adsorption,
the bacterial inoculum should be administered without any
delay to the wells containing polymyxins. Different derivatives
may be adsorbed differently to the plastics, depending on
their hydrophobicity, and perhaps on their cationic charge.
The best way to eliminate errors caused by the adsorption
is to add the compounds to the wells that already have the
target bacteria in the growth medium. The other CLSI-approved
reference method, agar dilution (AD) method, is not influenced
by the time-dependent inactivation of polymyxins and hence
may offer advantages over the BMD method. Even though
more laborious than the BMD method, it is currently used in
several laboratories (Vaara et al., 2008, 2017; Otter et al., 2017;
Tyrrell et al., 2019).
BUT WHAT ABOUT THE ACQUIRED
POLYMYXIN RESISTANCE?
The recent appearance of mobile colistin resistance (mcr)
genes has raised concern and a lot of publicity (Liu et al.,
2016; Poirel et al., 2017). This type of polymyxin resistance
(usually low-level resistance) may have its origin in China,
where colistin was used as a feed additive in animal husbandry.
Recently, China has announced to ban this use. Even more
worrisome are the strains resistant to polymyxins by other
mechanisms, such as those with altered mgrB that display high-
level resistance (Poirel et al., 2017). In the recent SENTRY
study (isolates collected worldwide in 2017), the frequency of
colistin resistance was still very rare, in Klebsiella pneumoniae
(n = 3753) only 0.4% and in E. coli (n = 7397) only
0.3% (SENTRY, 2019). However, among the global isolates
of carbapenemase-producing K. pneumoniae (n = 1703) and
E. coli (n = 407) collected during the SMART program
in 2015–2016, the prevalence of colistin resistance was 21
and 14%, respectively (Lob et al., 2017). In 2015, the
European Antimicrobial Surveillance Network (EARS-Net)
registered 33,100 deaths due to infections caused by antibiotic-
resistant bacteria. Out of these, 6.8% were caused by colistin-
resistant E. coli or K. pneumoniae and 0.5% by colistin-
resistant A. baumannii or P. aeruginosa (Cassini et al.,
2019). Regarding A. baumannii, the international SENTRY
program (1997–2016) reported that from the strains collected
in Europe (n = 3275), 6.1% were polymyxin-resistant and
64.4% were meropenem-resistant (Gales et al., 2019). In
the United States, the corresponding frequencies were 4.6
and 40.6% (n = 2461). Accordingly, polymyxin-resistant
strains are still rather rare and active at least in vitro
against the carbapenem-resistant strains of A. baumannii.
However, the resistance may develop during the therapy
(Tsuji et al., 2019).
As is the case for all antibiotics, polymyxin resistance will
eventually become more common. In this respect, however,
polymyxins seem to differ from all other antibiotics in a positive
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way. While not able to confer a lethal effect on the polymyxin-
resistant strains, polymyxins and their novel derivatives seem
to be able to sensitize polymyxin-resistant strains to various
“partner antibiotics” or “anti-Gram-positive antibiotics” that
enter the Gram-negative cell only if its OM permeability barrier
is first damaged by polymyxins to make it more permeable to
other noxious agents. Recent studies indicate that polymyxins
sensitize polymyxin-resistant strains to such partner antibiotics,
including rifampicin, azithromycin, clarithromycin, minocycline,
fusidic acid, zidovudine, and several other drugs (Tascini et al.,
2013; Brennan-Krohn et al., 2018; MacNair et al., 2018; Loose
et al., 2019). The derivative NAB739 shares this property as well
(Tyrrell et al., 2019). There are also attempts to assess whether
polymyxins could be derivatized to cover strains resistant to the
old polymyxins (Vaara, 2013; Brown and Dawson, 2017; Rabanal
and Cajal, 2017; Gallardo-Godoy et al., 2019).
CONCLUDING REMARK
Future will tell whether polymyxins join the expanding group
of antibiotics developed from primitive ancestors to modern
drugs. Improved polymyxins now under development respond
to previous challenges and some of them may turn out to be
more successful than the old polymyxins, thus strengthening our
armature before the antibiotic resistance crisis that we face now
grows into a catastrophe.
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